Free tool
FAERS Monitor: Fiasp Penfill
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 208751 or its brand name (Fiasp Penfill, Insulin Aspart). Reports on generic versions are filed under their own applications.
Reports
12,548
Serious
10,461
83% of reports
Hospitalization
6,133
Death reported
1,455
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased1,093
- nausea814
- dyspnoea754
- hypoglycaemia743
- vomiting717
- off label use711
- drug ineffective643
- abdominal pain542
- diarrhoea525
- condition aggravated522
- fatigue516
- acute kidney injury466
- general physical health deterioration430
- hyperglycaemia427
- sepsis419
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 35 |
| 2005 | 30 |
| 2006 | 35 |
| 2007 | 65 |
| 2008 | 110 |
| 2009 | 137 |
| 2010 | 111 |
| 2011 | 97 |
| 2012 | 146 |
| 2013 | 193 |
| 2014 | 238 |
| 2015 | 311 |
| 2016 | 353 |
| 2017 | 384 |
| 2018 | 711 |
| 2019 | 769 |
| 2020 | 893 |
| 2021 | 1,227 |
| 2022 | 1,291 |
| 2023 | 1,222 |
| 2024 | 1,406 |
| 2025 | 1,610 |
| 2026 | 1,174 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,611 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoglycaemiaSignal | 743 | 26.1 | 24.3 | 17,648 |
| hyperglycaemiaSignal | 427 | 19.9 | 18.1 | 7,554 |
| blood glucose increasedSignal | 1,093 | 9.8 | 9.2 | 8,628 |
| sepsisSignal | 419 | 6.3 | 5.7 | 1,873 |
| general physical health deteriorationSignal | 430 | 6.2 | 5.7 | 1,894 |
| acute kidney injurySignal | 466 | 5.1 | 4.7 | 1,546 |
| abdominal painSignal | 542 | 3.9 | 3.6 | 1,182 |
| condition aggravatedSignal | 522 | 2.9 | 2.6 | 647 |
| vomitingSignal | 717 | 2.6 | 2.4 | 694 |
| dyspnoeaSignal | 754 | 2.2 | 2.1 | 526 |
| nausea | 814 | 1.7 | 1.6 | 257 |
| diarrhoea | 525 | 1.4 | 1.3 | 52 |
| off label use | 711 | 1.4 | 1.3 | 71 |
| fatigue | 516 | 1.1 | 1.0 | 6 |
| drug ineffective | 643 | 0.8 | 0.8 | 28 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.